Ikerian closes Series B Financing with strategic partnership
Ikerian, a healthcare software platform company that organizes multimodal data at-scale, closes the first tranche of USD 8m Series B Financing to advance its AI platform alongside.
Nouscom Raises EUR 67.5m in Oversubscribed Series C Financing Round
Nouscom AG, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate of re-nowned international healthcare investors.
VISCHER advises Swiss Post on its acquisition of a stake in STERIPARC SA.
Yverdon-les-Bains-based STERIPARC SA is a joint venture for the outsourced processing of medical devices in Western Switzerland. Thanks to this partnership, Swiss Post is expanding its existing logistics services in the healthcare...
Rigeto Investors acquired prevention-center
A group of investors advised by Munich-based Rigeto Unternehmerkapital GmbH ("Rigeto") has acquired prevention-center as an add-on to the Matignon Group.
CITIC becomes largest shareholder in MedAlliance
Trustar Capital (formerly known as CITIC Capital Partners), a private equity affiliate of CITIC Capital Holdings Limited, has completed its over USD 50.0m investment in the Switzerland based global leading medical technology company MedAlliance SA ("MedAlliance"), becoming MedAlliance's single largest shareholder.
Oviva raises USD 21M to roll out digital diabetes treatment in Europe
Oviva raises USD 21M to roll out digital diabetes treatment in Europe.
The round was led by Swiss healthtech investor MTIP, joined by Earlybird as new investors. Existing investors AlbionVC, F-Prime Capital, Eight Roads Ventures...
Anaveon closes CHF 35 m Series A financing
Anaveon, an immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the Novartis Venture Fund. The company was founded with financing from BaseLaunch,...
Oculis in-licenses novel phase II-stage Anti-TNF alpha antibody fragment
Oculis SA, a clinical-stage biopharmaceutical company developing next-generation topical ophthalmic treatments in Lausanne, has entered into an agreement to in license a novel topical anti-TNF alpha antibody from Novartis. The...
Biovotion extends Series A Financing Round
VISCHER assists Harmony Medical Inc. as investor in the second closing of the ongoing CHF 10 m Series A financing round of Biovotion Ltd., Zürich. Biovotion Ltd is a leading wearable physiology monitoring company and provides...
Celgene acquires EngMab
Celgene (NASDAQ: CELG) has bought Swiss biotech EngMab for USD 600 million. EngMab's focus is on T-cell bispecific antibodies (TCBs). TCBs bind simultaneously to a target on a tumor cell and to the T-cell receptor complex, leading...